Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent Technologies (A) expands InfinityLab GPC/SEC portfolio to cater well to the needs of scientists in the macromolecular analysis.

Agilent (A) Boosts LSAG Segment With New GPC/SEC Solutions

SYDNEY, AUSTRALIA / ACCESSWIRE / June 13, 2023 / Barton Gold Holdings Ltd (ASX:BGD)(OTC PINK:BGHLF) is pleased to announce progress towards its development platform of 1.3M oz Gold. Processing has begun on the second 4.5 tonne cleanout of the Central Gawler Mill averaging 3 g/t for $A1.1m of gold.

Barton Gold Valuation Report

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf, Germany. The Agilent InfinityLab GPC/SEC portfolio has become even more comprehensive as it incorporates added value components from recent acquisition of Polymer Standard Service Ltd. (PSS) including a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scatter.

Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories' perceptions, aspirations, and challenges concerning implementing sustainability measures. Conducted on behalf of Agilent by the international market research firm Frost & Sullivan, the survey sought to understand how lab managers globally are thinking about sustainability and r.

Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use. Key features of the new BioTek 406 FX improve upon the benefits of the first-generation EL406 and include: Secon.

Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency

Agilent Technologies (A) strengthens its Life Sciences & Applied Markets Group (LSAG) segment with 6495 LC//TQ and Revident LC/Q-TOF.

Agilent (A) Boosts LCMS Portfolio With New Systems Launch

Analog Devices

Autodesk

Amgen

Aspen Technology Inc

Bank of America

Bank of New York Mellon

Blackrock Inc

Comcast

CME Group

Compass Minerals

Campbell Soup

Cheniere Energy Partners

Cisco Systems

Corteva Inc

Disney

Domino's Pizza

Ecolab

Equifax

Estee Lauder

Emerson Electric

Etsy

General Dynamics

Gilead Sciences

Alphabet

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The June 2023 Heat Map

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enables Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems in GMP-regulated facilities. The xCELLigence RTCA Software Pro enables data integrity controls to support regulatory requirements defined in FDA 21 CFR Part 11 an.

Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software. The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demand.

Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US) Environmental Protection Agency (EPA) Method 1633 (3rd draft). EPA Draft Method 1633 currently analyzes 40 PFAS compounds in wastewater and soil and is a complex and labor-intensive method, relying on multiple sample preparation and analysis steps. Success in runnin.

Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston, Texas. Agilent is a global leader in the mass spectrometry market, providing advanced, intelligent instruments featuring improved analytical performance solutions for analytical labs worldwide. “Agilent is leading the way in the trend towards developing more self-awa.

Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023

Agilent Technologies, Inc. stock has long traded at a premium valuation. The company has traditionally performed well, thanks to a solid positioning and continued M&A efforts.

Agilent Technologies Stock: Starting To Look Appealing

Fintel reports that on May 24, 2023, Goldman Sachs maintained coverage of Agilent Technologies (NYSE:A) with a Buy recommendation.

Goldman Sachs Maintains Agilent Technologies Buy Recommendation

Agilent Technologies' (A) second-quarter fiscal 2023 results reflect strength across LSAG and ACG segments.

Agilent (A) Q2 Earnings Match Estimates, Revenues Rise Y/Y

Agilent topped Wall Street's consensus earnings estimate in its latest quarter. However, market uncertainties caused the company to provide weaker-than-expected guidance.

Why Agilent Technologies Stock Is Sinking Today

Agilent Technologies (NYSE:A) Inc stock tumbled after it cut its outlook for its fiscal year 2023 while noting that demand from biotech companies had dried up in the difficult environment. “We expect this constrained capital environment to remain in place throughout the course of our fiscal year.

Agilent Technologies stock tumbles after it lowers outlook for its fiscal year

The laboratory instruments maker posted earnings of $1.27 per share, better than the $1.26 expected by analysts.

Agilent Gets a Downgrade After Strong Earnings. Here's Why.

Agilent Technologies, Inc. (NYSE:A ) Q2 2023 Earnings Conference Call May 23, 2023 4:30 PM ET Company Participants Parmeet Ahuja - IR Mike McMullen - President and CEO Robert McMahon - SVP and CFO Padraig McDonnell - President, Agilent CrossLab Group Sam Raha - President, Agilent Diagnostics & Genomics Group Jacob Thaysen - President, Agilent Life Science & Applied Markets Group Conference Call Participants Brandon Couillard - Jefferies Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Dan Leonard - Credit Suisse Mike Ryskin - Bank of America Dan Brennan - TD Cowen Jack Meehan - Nephron Patrick Donnelly - Citi Josh Waldman - Cleveland Research Liza Garcia - UBS Operator Ladies and gentlemen, welcome to the Agilent Technologies' Q2 2023 Earnings Call. My name is Sarah, and I will be coordinating your call today.

Agilent Technologies, Inc. (A) Q2 2023 Earnings Call Transcript

Agilent Technologies (A) came out with quarterly earnings of $1.27 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.13 per share a year ago.

Agilent Technologies (A) Meets Q2 Earnings Estimates

Shares of Agilent Technologies Inc. A, -0.35% fell after hours on Tuesday after the laboratory-equipment maker cut its full-year outlook to reflect “increased market uncertainties” and issued a weaker-than-expected third-quarter forecast. The company said it expected full-year sales of $6.93 billion to $7.03 billion, compared to a prior forecast of $7.03 billion to $7.1 billion given in February.

Agilent shares fall after ‘increased market uncertainties' weigh on outlook

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a core(1) basis. Second-quarter GAAP net income was $302 million, or $1.02 per share. This compares with $274 million, or 91 cents per share, in the second quarter of fiscal year 2022. Non-GAAP(2) net income was $377 million, or $1.27 per share during the quarter, c.

Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session. Jefferies Global Healthcare Conference Mike McMullen, Agilent President and CEO Wednesday, June 7 9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT Goldman Sachs 44th Annual Global Healthcare Conference Bob McMahon, Agilent CFO Tuesday, June 13 1:00 – 1:40 p.m. ET / 10.

Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences

Agilent's (A) results for the fiscal second quarter are expected to reflect strength across the LSAG, ACG and DGG segments.

Agilent Technologies (A) to Post Q2 Earnings: What's in Store?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board's (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO's original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA. Agilent resp.

Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents

Agilent (A) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Agilent Technologies Stock (A)